JP7425757B2 - 非分岐リンカーを伴うアミノ酸化合物およびその使用方法 - Google Patents

非分岐リンカーを伴うアミノ酸化合物およびその使用方法 Download PDF

Info

Publication number
JP7425757B2
JP7425757B2 JP2020572976A JP2020572976A JP7425757B2 JP 7425757 B2 JP7425757 B2 JP 7425757B2 JP 2020572976 A JP2020572976 A JP 2020572976A JP 2020572976 A JP2020572976 A JP 2020572976A JP 7425757 B2 JP7425757 B2 JP 7425757B2
Authority
JP
Japan
Prior art keywords
tetrahydro
naphthyridin
compound
deuterium
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020572976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529755A5 (enExample
JP2021529755A (ja
Inventor
カテリーナ・レフテリス
モーリーン・ライリー
ダレン・フィンケルスタイン
ニコール・クーパー
クリストファー・ベイリー
ジェイコブ・チャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliant Therapeutics Inc
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of JP2021529755A publication Critical patent/JP2021529755A/ja
Publication of JP2021529755A5 publication Critical patent/JP2021529755A5/ja
Priority to JP2024006536A priority Critical patent/JP2024055873A/ja
Application granted granted Critical
Publication of JP7425757B2 publication Critical patent/JP7425757B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
JP2020572976A 2018-06-27 2019-06-27 非分岐リンカーを伴うアミノ酸化合物およびその使用方法 Active JP7425757B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024006536A JP2024055873A (ja) 2018-06-27 2024-01-19 非分岐リンカーを伴うアミノ酸化合物およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690939P 2018-06-27 2018-06-27
US62/690,939 2018-06-27
PCT/US2019/039624 WO2020006315A1 (en) 2018-06-27 2019-06-27 Amino acid compounds with unbranched linkers and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024006536A Division JP2024055873A (ja) 2018-06-27 2024-01-19 非分岐リンカーを伴うアミノ酸化合物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2021529755A JP2021529755A (ja) 2021-11-04
JP2021529755A5 JP2021529755A5 (enExample) 2022-07-05
JP7425757B2 true JP7425757B2 (ja) 2024-01-31

Family

ID=68987528

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020572976A Active JP7425757B2 (ja) 2018-06-27 2019-06-27 非分岐リンカーを伴うアミノ酸化合物およびその使用方法
JP2024006536A Withdrawn JP2024055873A (ja) 2018-06-27 2024-01-19 非分岐リンカーを伴うアミノ酸化合物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024006536A Withdrawn JP2024055873A (ja) 2018-06-27 2024-01-19 非分岐リンカーを伴うアミノ酸化合物およびその使用方法

Country Status (24)

Country Link
US (3) US11396506B2 (enExample)
EP (1) EP3813818A4 (enExample)
JP (2) JP7425757B2 (enExample)
KR (1) KR20210043561A (enExample)
CN (1) CN112689507B (enExample)
AU (1) AU2019295769B2 (enExample)
BR (1) BR112020026278A2 (enExample)
CA (1) CA3104682A1 (enExample)
CL (1) CL2020003382A1 (enExample)
CR (1) CR20210041A (enExample)
CU (1) CU24693B1 (enExample)
DO (1) DOP2020000255A (enExample)
EA (1) EA202190134A1 (enExample)
EC (1) ECSP21005655A (enExample)
IL (2) IL279717B2 (enExample)
JO (1) JOP20200330A1 (enExample)
MX (1) MX2020014086A (enExample)
PE (1) PE20210137A1 (enExample)
PH (1) PH12020552260A1 (enExample)
SA (1) SA520420897B1 (enExample)
SG (1) SG11202013027RA (enExample)
TW (1) TWI841573B (enExample)
WO (1) WO2020006315A1 (enExample)
ZA (1) ZA202100211B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
CA3045491A1 (en) 2016-12-29 2018-07-19 Indalo Therapeutics, Inc. Integrin antagonists
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
TWI776067B (zh) 2018-06-29 2022-09-01 美商維托平面玻璃有限責任公司 可燒除保護性塗層
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
EP4076454A1 (en) * 2019-12-20 2022-10-26 Novartis AG Combination treatment of liver diseases using integrin inhibitors
IL293895A (en) * 2019-12-20 2022-08-01 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
GB202010626D0 (en) * 2020-07-10 2020-08-26 Univ Nottingham Compound
TW202235417A (zh) 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
GB202209228D0 (en) 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501051A (ja) 1998-01-27 2002-01-15 セルテック・セラピューティクス・リミテッド 薬剤として有用なフェニルアラニン誘導体
JP2002508355A (ja) 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
WO2008093064A1 (en) 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS
JP2009525296A (ja) 2006-01-31 2009-07-09 イエリニ・アクチェンゲゼルシャフト インテグリン阻害化合物およびその使用
JP2009539815A (ja) 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
JP2016515557A (ja) 2013-03-28 2016-05-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ αｖβ６インテグリンアンタゴニストとして有用なナフチリジン誘導体
US20180093984A1 (en) 2016-09-07 2018-04-05 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
JP2018514568A (ja) 2015-04-30 2018-06-07 サイフルーア ライフ サイエンシズ インコーポレイテッド テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
CN104817604B (zh) 2015-03-16 2017-08-04 邦泰生物工程(深圳)有限公司 一种β‑烟酰胺单核苷酸的纯化方法
KR20190026001A (ko) 2016-07-05 2019-03-12 더 락커펠러 유니버시티 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질
CN110167934B (zh) * 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US11046685B2 (en) * 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
EP3843728B1 (en) 2018-08-29 2025-04-30 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
CN115151566A (zh) 2019-11-15 2022-10-04 普利安特治疗公司 用于活化整合素的组合物和方法
KR20230049584A (ko) 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료
TW202235417A (zh) 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
US20230028658A1 (en) 2021-04-30 2023-01-26 Pliant Therapeutics, Inc. Expanded dosage regimens for integrin inhibitors
US20240350494A1 (en) 2021-09-03 2024-10-24 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
JP2024539645A (ja) 2021-10-14 2024-10-29 プライアント・セラピューティクス・インコーポレイテッド インテグリン阻害剤及び他の薬剤と組み合わせたその使用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508355A (ja) 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
JP2002501051A (ja) 1998-01-27 2002-01-15 セルテック・セラピューティクス・リミテッド 薬剤として有用なフェニルアラニン誘導体
JP2009525296A (ja) 2006-01-31 2009-07-09 イエリニ・アクチェンゲゼルシャフト インテグリン阻害化合物およびその使用
JP2009539815A (ja) 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
WO2008093064A1 (en) 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS
JP2016515557A (ja) 2013-03-28 2016-05-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ αｖβ６インテグリンアンタゴニストとして有用なナフチリジン誘導体
JP2018514568A (ja) 2015-04-30 2018-06-07 サイフルーア ライフ サイエンシズ インコーポレイテッド テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法
US20180093984A1 (en) 2016-09-07 2018-04-05 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters，2004年，Vol.14，pp.4411-4415

Also Published As

Publication number Publication date
CN112689507A (zh) 2021-04-20
AU2019295769A1 (en) 2021-02-11
IL279717A (en) 2021-03-01
SG11202013027RA (en) 2021-01-28
PH12020552260A1 (en) 2021-08-16
CL2020003382A1 (es) 2021-05-14
CU24693B1 (es) 2024-02-07
CN112689507B (zh) 2024-07-30
EP3813818A4 (en) 2023-01-11
DOP2020000255A (es) 2021-05-16
IL279717B2 (en) 2024-05-01
AU2019295769B2 (en) 2024-05-23
US20200123151A1 (en) 2020-04-23
US11396506B2 (en) 2022-07-26
US11858931B2 (en) 2024-01-02
EP3813818A1 (en) 2021-05-05
WO2020006315A1 (en) 2020-01-02
CU20210001A7 (es) 2021-08-06
KR20210043561A (ko) 2021-04-21
US20220289743A1 (en) 2022-09-15
TW202010492A (zh) 2020-03-16
SA520420897B1 (ar) 2024-03-30
US20240294520A1 (en) 2024-09-05
BR112020026278A2 (pt) 2021-04-06
EA202190134A1 (ru) 2021-03-26
JOP20200330A1 (ar) 2020-12-20
CA3104682A1 (en) 2020-01-02
ECSP21005655A (es) 2021-02-26
TWI841573B (zh) 2024-05-11
JP2021529755A (ja) 2021-11-04
MX2020014086A (es) 2021-04-13
IL279717B1 (en) 2024-01-01
CR20210041A (es) 2021-03-02
IL308960A (en) 2024-01-01
PE20210137A1 (es) 2021-01-21
JP2024055873A (ja) 2024-04-18
ZA202100211B (en) 2025-05-28

Similar Documents

Publication Publication Date Title
US11858931B2 (en) Amino acid compounds with unbranched linkers and methods of use
US11952376B2 (en) Substituted amino acids as integrin inhibitors
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
JP7379467B2 (ja) Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
JP7395730B2 (ja) ヘテロ環式ｒｉｐ１阻害化合物
KR20200139676A (ko) 아미노산 화합물 및 사용 방법
CN114728958A (zh) Rip1抑制性化合物和制备与使用其的方法
EA033626B1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-а]ПИРИДИНКАРБОКСАМИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИХ
WO2018119087A1 (en) Amino acid compounds and methods of use
CA2879400A1 (en) Deuterated ibrutinib
CA3042710A1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
JP2019504900A (ja) プロテインキナーゼ阻害剤である新規な２，３，５−置換チオフェン化合物
CA3201754A1 (en) Preparation of tetrahydroindazole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
HK40049583A (en) Amino acid compounds with unbranched linkers and methods of use
BR122023025996A2 (pt) Compostos de aminoácidos, composição farmacêutica e kit compreendendo os mesmos, seus usos, e seu método de produção
WO2026047577A1 (en) Hydroquinazoline derivatives and treatment of a disease or disorder using the same
EA048929B1 (ru) Соединения, ингибирующие rip1, и способы их получения и применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240119

R150 Certificate of patent or registration of utility model

Ref document number: 7425757

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150